Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atorvastatin + esomeprazole is a combination of two small molecule drugs, each with distinct mechanisms and indications. Atorvastatin is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and reduce the risk of cardiovascular disease by inhibiting endogenous cholesterol synthesis in the liver. Esomeprazole is a proton pump inhibitor (PPI) that reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, primarily indicated for gastroesophageal reflux disease (GERD), peptic ulcer disease, and other conditions involving excessive stomach acid production. This combination does not have a unique brand or product name and is not marketed as a fixed-dose combination; it refers to concurrent use of both agents. Coadministration may increase plasma concentrations of atorvastatin due to metabolic interactions involving cytochrome P450 enzymes, particularly CYP3A4 and CYP2C19[1][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atorvastatin + esomeprazole.